• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    New insider Zhang Hong claimed ownership of 240,481 shares (SEC Form 3)

    8/23/24 3:11:44 PM ET
    $ESLA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ESLA alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Zhang Hong

    (Last) (First) (Middle)
    5858 HORTON STREET
    SUITE 370

    (Street)
    EMERYVILLE CA 9460

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    08/14/2024
    3. Issuer Name and Ticker or Trading Symbol
    Estrella Immunopharma, Inc. [ ESLA ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) X Other (specify below)
    Chairperson of the Board
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Common Stock 240,481 I See Footnote(1)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Represents 240,481 shares of common stock of the issuer held by CoFame Investment Holding LLC, the manager of which is the Reporting Person. By virtue of this relationship, the Reporting Person may be deemed to beneficially own the 240,481 shares of common stock of the issuer held by CoFame Investment Holding LLC.
    Remarks:
    Exhibit List: Exhibit 24 - Power of Attorney.
    /s/ Jaewon Chang, as attorney-in-fact 08/23/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ESLA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ESLA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ESLA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Executive Officer Liu Cheng

      4 - Estrella Immunopharma, Inc. (0001844417) (Issuer)

      2/14/25 4:30:20 PM ET
      $ESLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Xu Jiandong

      4 - Estrella Immunopharma, Inc. (0001844417) (Issuer)

      2/14/25 4:30:12 PM ET
      $ESLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • New insider Zhang Hong claimed ownership of 240,481 shares (SEC Form 3)

      3 - Estrella Immunopharma, Inc. (0001844417) (Issuer)

      8/23/24 3:11:44 PM ET
      $ESLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ESLA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin's Lymphomas

      Estrella Immunopharma, Inc. (NASDAQ:ESLA) ("Estrella" or the "Company"), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that the first patient has been dosed in the second cohort of its dose escalation study of Phase I/II STARLIGHT-1 trial for EB103, a CD19-redirected ARTEMIS® T-cell therapy to treat patients with Advanced B-Cell Non-Hodgkin's Lymphomas (NHL). The second cohort will evaluate EB103 at a higher dose level following a review of safety data from the first dose cohort. As previously announced, no dose-limiting toxicities (DLTs) or treatment-related serious adverse e

      5/29/25 8:01:00 AM ET
      $ESLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a Price Target of $14.00 From CB Capital Partners

      Estrella Immunopharma, Inc. (NASDAQ:ESLA) ("Estrella" or the "Company"), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that CB Capital Partners has initiated coverage on the Company with a Buy rating and a price target of $14.00. "We appreciate CB Capital's detailed evaluation of our proprietary ARTEMIS® T-cell platform and the progress we have made with EB103," said Dr. Cheng Liu, President and Chief Executive Officer of Estrella. "Their report highlights the unique attributes of our approach to T-cell therapy and underscores the potential for our pipeline to deliver transform

      3/5/25 8:00:00 AM ET
      $ESLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort

      Estrella Immunopharma, Inc. (NASDAQ:ESLA, ESLAW)) ("Estrella" or the "Company"), a clinical stage biopharmaceutical company developing CD19-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced the successful completion of the first dose cohort in its ongoing STARLIGHT-1 Phase I/II clinical trial. Following a review of safety and efficacy data, the Data and Safety Monitoring Board (DSMB) has approved the initiation of the second dose cohort, which will administer 5 million receptor-positive T cells per kilogram of body weight of EB103 CD19-Redirected ARTEMIS® T-cell therapy. The first dose cohort included patients with relapsed/refractory B-cell non-Ho

      2/21/25 8:30:00 AM ET
      $ESLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ESLA
    Leadership Updates

    Live Leadership Updates

    See more
    • Estrella Immunopharma Announces Appointment of Hong Zhang as Chairperson and Board Member

      Estrella Immunopharma, Inc. (NASDAQ:ESLA, ESLAW))) ("Estrella", "Estrella Immunopharma", or the "Company"), a clinical stage biopharmaceutical company focused on developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancers and autoimmune diseases, today announced the appointment of Hong Zhang as Chairperson and a member of its Board of Directors. This appointment comes shortly after the Company dosed the first patient in its Phase I/II clinical trial (STARLIGHT-1) for EB103, an autologous T-cell therapy for adult patients with relapsed or refractory (R/R) B-cell Non-Hodgkin's Lymphoma (NHL). Ms. Zhang's appointment increases the size of Estrella's Board from five to six dire

      8/14/24 12:00:00 PM ET
      $ESLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ESLA
    SEC Filings

    See more
    • Estrella Immunopharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Estrella Immunopharma, Inc. (0001844417) (Filer)

      5/29/25 11:13:18 AM ET
      $ESLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Estrella Immunopharma Inc.

      10-Q - Estrella Immunopharma, Inc. (0001844417) (Filer)

      5/14/25 4:31:13 PM ET
      $ESLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Estrella Immunopharma Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - Estrella Immunopharma, Inc. (0001844417) (Filer)

      5/2/25 5:00:26 PM ET
      $ESLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care